The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Quva is initiating a recall on certain lots of Quva's Ropivacaine, Epinephrine, Clonidine, and Ketorolac ("R.E.C.K.") in Sodium Chloride Solution, 50 mL fill, 50 mL syringe product (Product Code 70092-1433-50) ("R.E.C.K. Product") within their expiry period compounded by Quva's Sugar Land, Texas outsourcing facility (NSF-100). Quva's supplier, Camber Pharmaceuticals, Inc. ("Camber"), recently initiated a recall of its FDA-approved Ketorolac Tromethamine Injection USP 60 mg/2 mL (30 mg/mL) vial products (NDC Nos. 31722-307-25 (carton) and 31722 307-02 (vial)). Camber's FDA-approved Ketorolac Tromethamine USP product is a drug product component used in Quva's R.E.C.K. Product. Therefore, Quva has initiated a recall of all affected lots of R.E.C.K. Product compounded using Camber's recalled Ketorolac product. The RECK Product includes 222 lots that were distributed by Quva to 910 hospitals between July 17, 2025, and October 1, 2025.

Quva's manufacturing process for its R.E.C.K. Product incorporates thorough incoming component and post-production inspection, sterile filtration steps, and release testing. No adverse events or patient injuries have been reported in connection with the administration of the affected lots of R.E.C.K. Product.

This recall is being conducted to the pharmacy level. Quva Pharma notified FDA on October 9, 2025, prior to initiation of the recall.